Lilly prices new clot-buster at 31% premium

Eli Lilly launched its new blood thinner in its first market today: the U.K. Effient/Efient (prasugrel) is priced 31 percent higher than its rival Plavix, the world's leading anticoagulant marketed by Bristol-Myers Squibb and Sanofi Aventis. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.